logo-loader
HealthPharma & Biotech
Bard1 Life Sciences Ltd

BARD1 Life Sciences Ltd targets cash injection

The halt will remain in place until Wednesday 5th July 2017.

Syringe.jpg
BARD1 is focused on tests for cancer

BARD1 Life Sciences Ltd (ASX:BD1) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.

The company is focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer.

The halt will remain in place until the opening of trade on Wednesday 5th July 2017, or earlier if an announcement is made to the market.

Quick facts: Bard1 Life Sciences Ltd

Price: $0.03

Market: ASX
Market Cap: $39.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Technology Metals Australia's DFS reveals high-value, long-life for...

Technology Metals Australia (ASX:TMT) executive director Ian Prentice updates Proactive Investors on the DFS results from its Gabanintha Vanadium Project in WA, which has ascribed the project a valuation pre-tax of A$1.32 billion.    Prentice said the study results...

2 hours, 19 minutes ago

2 min read